Trending/Dr. Stephen Ansell

Brentuximab vedotin may improve overall survival in patients with Hodgkin Lymphoma
ROCHESTER, Minn. — A study led by researchers from Mayo Clinic Comprehensive Cancer Center has found that the addition of brentuximab vedotin to standard chemotherapy…
Special Topics
Sign up

Mayo Clinic Connect
An online patient support community